President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to reduce prices for their obesity treatments Zepbound and Wegovy. Here’s what we know.

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication more accessible nationwide.

A new weight-loss drug from Eli Lilly & Co. helped patients shed as much weight as popular shots like Zepbound, giving the company another edge in the fast-growing obesity market.

Eli Lilly and Walmart said they have teamed up to boost access to the pharma giant's weight loss drug Zepbound, allowing U.S. patients to access vials of the blockbuster injection at direct-to-consumer prices through retail locations for the first time.

The White House is expected to announce a deal for lower prices of obesity drugs from Novo Nordisk and Eli Lilly on Thursday during an event, according to sources familiar with the situation, pushing shares of the two companies higher as investors bet on increased patient access in government health programs.

Eli Lilly and Company and Walmart have announced a partnership to offer Zepbound single-dose vials at Walmart pharmacies. The move will start nationwide in mid-November and will have direct-to-consumer pricing through LillyDirect.

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest move by the company to expand its direct-to-consumer services.

Eli Lilly said on Wednesday it is partnering with Walmart to sell its weight-loss treatment Zepbound at the retailer's pharmacies across the United States at direct-to-consumer prices.

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site to the west in Bristol. The next step after the Mounjaro and Zepbound manufacturer's site plan is approved is a development agreement.